MRK vs ONC
Merck & Co. vs BeOne Medicines AG — AI-powered side-by-side comparison
VS
ONC
BeOne Medicines AG
64
Buy
| Metric | MRK | ONC |
|---|
| AI Score |
70
|
64
|
| Price |
$130.34
|
$359.20
|
| P/E Ratio |
103.53×
|
29.70×
|
| ROE |
34.7%
|
6.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
87.8%
|
| Debt / Equity |
1.29×
|
0.22×
|
| Dividend Yield |
2.6%
|
0.0%
|
| RSI (14) |
64.5
|
84.1
|
| Beta |
0.207
|
0.5
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for MRK versus ONC.
MRK leads by 6 points.
MRK scores 70/100 (Buy) versus ONC at 64/100 (Buy).
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
ONC Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 36.2% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 86.0 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 36.2% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 86.0 is expensive by classic value standards — Value
- Price-to-book of 8.7x prices in significant intangible value — Value
- RSI at 84 is in overbought territory — Technical